Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant, Kaken sign license deal to develop new chemical entity for psoriasis
If approved, KP-470 will represent a novel drug with an alternate mechanism of action in the topical treatment of the disease. Under the terms of the licensing agreement,
If approved, KP-470 will represent a novel drug with an alternate mechanism of action in the topical treatment of the disease. Under the terms of the licensing agreement,
The round was led by New Enterprise Associates, with participation from 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital,
The Phase 1 clinical trial is a randomized, observer-blinded, placebo-controlled, single center study. This study, in approximately 65 healthy adults, will investigate two dose levels of VLA1601 when
Lusutrombopag (S-888711) is an investigational, once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist. In the US, Shionogi is seeking FDA approval of lusutrombopag for the treatment of thrombocytopenia
This recommendation will now go forward to the European Commission for ratification and implementation over the next two to three months. Feraccru, the Company’s lead asset, is currently
The Alkindi patent, entitled "Treatment of Adrenal Insufficiency", is a pharmaceutical composition-of-matter patent protecting Alkindi's proprietary formulation as a treatment for adrenal insufficiency in paediatric and elderly adult
The acquisition creates a unique AI-enabled research centre that can radically reduce the time it takes for drug candidates to enter clinical testing and deliver significantly higher success
Supported by a £4.7million award from Department of Health and Social Care, managed by Innovate UK, the project aims to take two new vaccine candidates through to a
ATUM CEO Dr Jeremy Minshull said: “We love everything about Just’s mission, and we are delighted that our Leap-In technology will be used to help democratize access to
INBRIJA is an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen. Under the Prescription Drug User Fee Act